Trials / Completed
CompletedNCT05633264
A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan
Deucravacitinib Post-marketing Surveillance in Patients With Psoriasis in Japan
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 369 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and effectiveness of deucravacitinib for the treatment of plaque psoriasis (PsO) in Japan participants.
Conditions
Timeline
- Start date
- 2022-12-05
- Primary completion
- 2025-05-28
- Completion
- 2025-05-28
- First posted
- 2022-12-01
- Last updated
- 2025-07-03
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05633264. Inclusion in this directory is not an endorsement.